Viridian Therapeutics Statistics
Total Valuation
VRDN has a market cap or net worth of $2.18 billion. The enterprise value is $1.72 billion.
Important Dates
The next confirmed earnings date is Wednesday, November 5, 2025, before market open.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
VRDN has 93.09 million shares outstanding. The number of shares has increased by 34.69% in one year.
| Current Share Class | 93.09M |
| Shares Outstanding | 93.09M |
| Shares Change (YoY) | +34.69% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 87.25% |
| Float | 66.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 30.90 |
| Forward PS | 12,180.77 |
| PB Ratio | 5.64 |
| P/TBV Ratio | 6.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 24.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.28, with a Debt / Equity ratio of 0.04.
| Current Ratio | 11.28 |
| Quick Ratio | 11.06 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -108.36 |
Financial Efficiency
Return on equity (ROE) is -49.89% and return on invested capital (ROIC) is -32.69%.
| Return on Equity (ROE) | -49.89% |
| Return on Assets (ROA) | -30.40% |
| Return on Invested Capital (ROIC) | -32.69% |
| Return on Capital Employed (ROCE) | -62.33% |
| Revenue Per Employee | $495,028 |
| Profits Per Employee | -$1.88M |
| Employee Count | 143 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.21% in the last 52 weeks. The beta is 0.95, so VRDN's price volatility has been similar to the market average.
| Beta (5Y) | 0.95 |
| 52-Week Price Change | +1.21% |
| 50-Day Moving Average | 20.83 |
| 200-Day Moving Average | 16.85 |
| Relative Strength Index (RSI) | 53.13 |
| Average Volume (20 Days) | 1,548,457 |
Short Selling Information
The latest short interest is 9.99 million, so 10.73% of the outstanding shares have been sold short.
| Short Interest | 9.99M |
| Short Previous Month | 10.24M |
| Short % of Shares Out | 10.73% |
| Short % of Float | 14.92% |
| Short Ratio (days to cover) | 13.18 |
Income Statement
In the last 12 months, VRDN had revenue of $70.79 million and -$268.64 million in losses. Loss per share was -$3.31.
| Revenue | 70.79M |
| Gross Profit | -70.33M |
| Operating Income | -328.12M |
| Pretax Income | -301.97M |
| Net Income | -268.64M |
| EBITDA | -327.66M |
| EBIT | -328.12M |
| Loss Per Share | -$3.31 |
Full Income StatementBalance Sheet
The company has $490.90 million in cash and $20.89 million in debt, giving a net cash position of $470.01 million or $5.05 per share.
| Cash & Cash Equivalents | 490.90M |
| Total Debt | 20.89M |
| Net Cash | 470.01M |
| Net Cash Per Share | $5.05 |
| Equity (Book Value) | 502.97M |
| Book Value Per Share | 3.82 |
| Working Capital | 521.22M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$325.97 million and capital expenditures -$369,000, giving a free cash flow of -$326.34 million.
| Operating Cash Flow | -325.97M |
| Capital Expenditures | -369,000 |
| Free Cash Flow | -326.34M |
| FCF Per Share | -$3.51 |
Full Cash Flow StatementMargins
| Gross Margin | -99.35% |
| Operating Margin | -463.52% |
| Pretax Margin | -426.58% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VRDN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -34.69% |
| Shareholder Yield | -34.69% |
| Earnings Yield | -12.28% |
| FCF Yield | -14.92% |
Analyst Forecast
The average price target for VRDN is $39.20, which is 67.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $39.20 |
| Price Target Difference | 67.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 405.82% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 13, 2020. It was a reverse split with a ratio of 1:15.
| Last Split Date | Nov 13, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
